Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F13-PEI1.8k-2
- Development stage
- Preclinical
- Lead developer
- 华东师范大学
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intratumoral
01
Overview
F13-PEI1.8k-2 is a fluorinated derivative of branched polyethylenimine (PEI) with a molecular weight of 1.8 kDa, specifically modified with perfluorohexyl (F13) alkyl chains. Developed primarily as a non-viral vector for gene delivery, this polymer addresses the efficiency-toxicity trade-off common in cationic polymers. The incorporation of fluorine atoms leverages the fluorous effect to enhance cellular uptake and facilitate endosomal escape through membrane disruption and the proton sponge effect, while the low-molecular-weight PEI backbone ensures significantly lower cytotoxicity compared to high-molecular-weight variants like PEI 25k. The -2 designation refers to the specific molar ratio of the fluorinated grafting agent to the polymer amines. It is utilized in preclinical research for the delivery of plasmid DNA, siRNA, and mRNA, with potential applications in oncology and genetic disease therapies.
- Other names
- F13-PEI1.8kF-13-PEI1.8kF 13-PEI1.8kFluorinated polyethylenimine 1.8kF-PEI(1.8k)-2
02
Targets
DNA
Beyond the preview
Go deeper on F13-PEI1.8k-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F13-PEI1.8k-2.